Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells aim to keep dialysis lifelines open

NCT ID NCT04392206

Recruiting now Disease control Sponsor: Houssam Farres, M.D. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-stage trial tests whether stem cells from donated fat tissue can help prevent narrowing at the connection point of a dialysis access site in people with end-stage kidney disease. The study enrolls 15 adults who are already scheduled for fistula creation. Researchers will monitor for side effects and measure how well the access site works over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adipose Derived Mesenchymal Stem Cells (AMSC)
What this could lead to
If safe and effective, this approach could help people on dialysis maintain better blood flow through their access site, reducing the need for repeat procedures.
What could go wrong
This is a very early Phase 1 trial with only 15 participants, so it is primarily testing safety, not effectiveness. There is a risk of inflammation, infection, or blood flow problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.